CSChaohong Sun

Chaohong Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chaohong Sun has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Figure S2 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    Related to figure 2. (A) SPR sensorgrams of WRN WT and G729D treated with AC1 and AC2 (B) SPR sensorgram of WRN WT and D526_P530del treated with AC1 (C) Top: IGV browser window of whole exome sequencing variant calling file for AC1-resistant SW48 cells (D526_P530del) indicating a A->G mutation in the splice acceptor site before exon 13. Bottom: Sanger sequencing trace of a portion of the WRN helicase region indicating a mixed sequence of wildtype WRN and a 15 amino acid deletion. (D) Viability of WRN L528S/G729D SW48 cells or DMSO control cells treated with increasing doses of AC1 (left) and AC2 (right) normalized to DMSO treated cells measured with CTG after 3 days of treatment (n=3). (E) SPR sensorgram of WT WRN and L528S treated with AC1

  • Open Access

    Table S2 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

  • Open Access

    Table S1 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    Summary of cellular and biochemical IC50 values for each WRN mutation and inhibitor.

  • Open Access

    Figure S4 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    Related to figure 4. (A) SPR sensorgram of WRN WT and F730L treated with AC1 (B) As in (A) with AC2 (C) As in (A) with C727R (D) SPR sensorgram of WRN WT and L528S treated with HRO761 (E) SPR sensorgram of WRN WT and I852F treated with AC1

  • Open Access

    Data from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    The Werner syndrome helicase (WRN) is a promising target for cancers with microsatellite instability (MSI), leading to the initiation of at least five phase I clinical trials. Acquired resistance is a substantial obstacle to obtaining lasting benefits from targeted therapies in oncology and may be particularly acute in the setting of mismatch repair–deficient (dMMR) tumors, which can sample increased fitness landscapes owing to a higher mutational burden. In this study, we characterized resistance mechanisms using the clinical candidate HRO761 and two novel inhibitors in MSI cell lines and xenograft models. We observed the rapid emergence of resistance both in vitro and in vivo, with sequencing revealing clustered mutations within the WRN helicase domain. Computational structural analyses indicated that these mutations either directly interfere with inhibitor binding or alter the protein conformation required for inhibitor engagement. Notably, although most mutations conferred broad resistance across all three compounds, we identified specific alterations (L528S, C727R, and F730L) that exhibited selectivity between chemical scaffolds. This chemotype-specific resistance profile suggests opportunities for developing next-generation inhibitors that retain activity against resistant variants and for implementing rational treatment strategies with existing inhibitors. Overall, our findings demonstrate that on-target resistance to WRN inhibitors emerges rapidly in dMMR backgrounds but also highlight potential approaches to overcome resistance, supporting the continued development of WRN-targeted therapies for MSI cancers.

  • Open Access

    Figure S1 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    Related to figure 1. (A) SPR sensorgrams of WT WRN treated with AC1 and AC2. (B) DNA unwinding activity of wildtype WRN in the presence of AC1 and AC2. (C) Molecular docking of AC1 bound to the WRN helicase region (D) Viability of WRN dependent and independent cell lines treated with AC1 (left) or AC2 (right) after 3 days inhibitor treatment measured with CTG n=2 (E) Fold change γH2A.X immunofluorescence staining normalized to DMSO control in WRN dependent and independent cells treated with AC1 (left) or AC2 (right) for 3 days. n=2 for all lines except SW620 n=1

  • Open Access

    Figure S3 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    Related to figure 3. (A) Mean tumor volume measurements (± SEM) in a HRO71-resistant SW48 xenograft model treated with vehicle or 120 mg/kg HRO761 (n = 10 mice per treatment group). (B) Mean body weight of mice corresponding to figure 3A (C) Mean body weight of mice corresponding to figure S3A (D) Heatmap of WES results for tumors treated with HRO761 in Fig 3A, B (E) Experiment level mutation results of HRO761 resistance experiments (F) Sanger sequencing results of HRO761 dose ramp-up resistance experiments (G) SPR sensorgram of WRN WT and G729D treated with HRO761 (H) As in G with C727R (I) As in G with F730L (J) As in G with D526_P530del

  • Open Access

    Figure S5 from Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    DNA unwinding activity of WRN mutant proteins

  • Open Access

    Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors

    by Faith Fowler, Jessica Gajda, Amirhossein Mafi, Aileen Kelly, Cynthia L. Jeffries, Phuong Le, Lei Shi, Mariam George, Nathaniel Elsen, Alla V. Korepanova, et al.

    The Werner syndrome helicase (WRN) is a promising target for cancers with microsatellite instability (MSI), leading to the initiation of at least five phase I clinical trials. Acquired resistance is a substantial obstacle to obtaining lasting benefits from targeted therapies in oncology and may be particularly acute in the setting of mismatch repair–deficient (dMMR) tumors, which can sample increased fitness landscapes owing to a higher mutational burden. In this study, we characterized resistance mechanisms using the clinical candidate HRO761 and two novel inhibitors in MSI cell lines and xenograft models. We observed the rapid emergence of resistance both in vitro and in vivo, with sequencing revealing clustered mutations within the WRN helicase domain. Computational structural analyses indicated that these mutations either directly interfere with inhibitor binding or alter the protein conformation required for inhibitor engagement. Notably, although most mutations conferred broad resistance across all three compounds, we identified specific alterations (L528S, C727R, and F730L) that exhibited selectivity between chemical scaffolds. This chemotype-specific resistance profile suggests opportunities for developing next-generation inhibitors that retain activity against resistant variants and for implementing rational treatment strategies with existing inhibitors. Overall, our findings demonstrate that on-target resistance to WRN inhibitors emerges rapidly in dMMR backgrounds but also highlight potential approaches to overcome resistance, supporting the continued development of WRN-targeted therapies for MSI cancers.


  • Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK

    by Kamaldeep Dhami, Anirban Chakraborty, Tarikere L. Gururaja, Leo W.-K. Cheung, Chaohong Sun, Felix DeAnda, XiaoDong Huang

    The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib irreversibly binds BTK at Cys 481 , inhibiting its kinase activity and thus blocking transduction of B cell receptor (BCR) signaling. Although ibrutinib is durably effective in patients with B cell malignancies, many patients still develop ibrutinib-resistant disease. Resistance can arise because of mutations at the ibrutinib-binding site in BTK. Here, we characterized the mechanism by which two BTK mutations, C481F and C481Y, may lead to ibrutinib resistance. Both mutants lacked detectable kinase activity in in vitro kinase assays. Structural modeling suggested that bulky Phe and Tyr side chains at position 481 sterically hinder access to the ATP-binding pocket in BTK, contributing to loss of kinase activity. Nonetheless, BCR signaling still propagated through BTK C481F and C481Y mutants to downstream effectors, the phospholipase PLCγ2 and the transcription factor NF-κB. This maintenance of BCR signaling was partially achieved through the physical recruitment and kinase-independent activation of hematopoietic cell kinase (HCK). Upon BCR activation, BTK C481F or C481Y was phosphorylated by Src family kinases at Tyr 551 , which then bound to the SH2 domain of HCK. Modeling suggested that this binding disrupted an intramolecular autoinhibitory interaction in HCK. Activated HCK subsequently phosphorylated PLCγ2, which propagated BCR signaling and promoted clonogenic cell proliferation. This kinase-independent mechanism could inform therapeutic approaches to CLL bearing either the C481F or C481Y BTK mutants.